A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature in vivo

…, E Trachsel, M Kaspar, C Schliemann… - … journal of cancer, 2008 - Wiley Online Library
The alternatively spliced extra‐domain B of fibronectin is one of the best characterized markers
of tumor angiogenesis. Similarly, the extra‐domain A (EDA), which can also be inserted …

[HTML][HTML] PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups

…, C Müller-Tidow, T Spieker, C Schliemann… - PloS one, 2015 - journals.plos.org
Background Immunotherapy can become a crucial therapeutic option to improve prognosis
for lung cancer patients. First clinical trials with therapies targeting the programmed cell …

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

…, K Schäfer-Eckart, C Schliemann… - Blood, The Journal …, 2022 - ashpublications.org
Biallelic mutations of the CEBPA gene (CEBPA bi ) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm ) is poorly …

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

…, Q Chen, L Angenendt, C Schliemann… - Blood, The Journal …, 2021 - ashpublications.org
The prognosis of patients with acute myeloid leukemia (AML) remains dismal, highlighting
the need for novel innovative treatment strategies. The application of chimeric antigen …

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

…, J Lohmeyer, M Michaelis, V Hornung, C Schliemann… - Nature medicine, 2017 - nature.com
The nucleoside analog cytarabine (Ara-C) is an essential component of primary and salvage
chemotherapy regimens for acute myeloid leukemia (AML). After cellular uptake, Ara-C is …

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

C Schliemann, A Palumbo… - Blood, The Journal …, 2009 - ashpublications.org
The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive
strategy for anticancer therapy, but is largely unexplored in hematologic malignancies. In …

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

C Röllig, M Kramer, C Schliemann… - Blood, The Journal …, 2020 - ashpublications.org
In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start
is recommended due to the poor prognosis of untreated acute leukemia. We explored the …

Genome instability in multiple myeloma

CJ Neuse, OC Lomas, C Schliemann, YJ Shen… - Leukemia, 2020 - nature.com
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal
proliferation of plasma cells and a heterogenous genomic landscape. Copy number and …

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia

KL Gutbrodt, C Schliemann, L Giovannoni… - Science translational …, 2013 - science.org
Acute myeloid leukemia (AML) is a rapidly progressing disease that is accompanied by a
strong increase in microvessel density in the bone marrow. This observation prompted us to …

[PDF][PDF] Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia

…, C Wickenhauser, L Angenendt, C Schliemann… - Cell Stem Cell, 2023 - cell.com
Inter-patient variability and the similarity of healthy and leukemic stem cells (LSCs) have
impeded the characterization of LSCs in acute myeloid leukemia (AML) and their differentiation …